BD, Techcyte Announce Strategic Collaboration to Offer AI-Based Digital Cervical Cytology System for Pap Testing
- None.
- None.
Insights
From a medical research perspective, the strategic collaboration between BD and Techcyte presents a significant advancement in the field of cervical cancer screening. The development of an AI-based algorithm for identifying cervical cancer and precancerous lesions could potentially increase the accuracy and efficiency of Pap test evaluations. This is particularly important considering that cervical cancer is the fourth most common cancer among women globally, with a high mortality rate that could be mitigated through improved screening processes.
The integration of AI into cytology not only addresses the shortage of healthcare laboratory technicians but also combats issues such as eye strain and fatigue that can affect manual evaluations. Moreover, the compatibility of the Techcyte platform with common liquid-based cytology preparations and whole-slide imagers suggests a versatile application in existing laboratory workflows. The CE marking and pursuit of FDA approval underline the system's readiness for clinical use, potentially influencing laboratory adoption rates and market penetration in the near future.
The collaboration between BD and Techcyte is likely to have a positive impact on the stock market for both companies, especially if the AI-based diagnostic system gains FDA approval and becomes widely adopted. Investors should note the potential for this technology to disrupt the traditional Pap test market by offering a more standardized and reproducible method for cervical cancer screening.
The market for cervical cancer diagnostics could see increased competition as a result of this innovation, with BD potentially securing a stronger foothold. The system's ability to integrate with existing laboratory infrastructure and its compatibility with various whole-slide imagers could facilitate a smoother transition for labs and reduce barriers to entry. As healthcare continues to embrace digital and AI solutions, this collaboration positions BD and Techcyte as pioneers in the digital transformation of cytology services.
From an economic standpoint, the introduction of an AI-based cervical cytology system could have far-reaching implications for healthcare cost management. By increasing the efficiency of Pap test evaluations and reducing the potential for human error, healthcare providers may experience a decrease in repeated testing and associated costs. The ability to conduct evaluations remotely also has the potential to reduce healthcare delivery costs and expand access to cervical cancer screening in underserved regions.
However, the initial investment in the AI-based system and the cost to train personnel could be substantial. It is crucial to assess the cost-benefit ratio and the potential for this technology to be cost-effective in the long term. The economic impact will also depend on the system's adoption rate, reimbursement policies and the extent to which it can replace or complement existing screening methods.
AI-Based Algorithm Aims to Enable Cytotechnologists and Pathologists to Efficiently Identify Evidence of Cervical Cancer and Precancerous Lesions
The agreement enables BD to deliver a complete solution that aims to reduce the potential for human error and enable greater throughput, so that labs can achieve their results with greater standardization, reproducibility, and efficiency from a Pap test, also known as a Pap smear.
Traditionally, Pap tests have been conducted by taking a sample from a patient and placing it on a glass slide that is visually evaluated by a cytotechnologist or pathologist using a microscope. With the digital cervical cytology system, the samples can be scanned, converted to a digital slide image, and then reviewed on a computer monitor in a lab or from a remote location. In addition, the digital cervical cytology system uses an AI-based algorithm to prioritize and present clinically relevant cells for visual evaluation.
"There is a shortage of health care laboratory technicians, and the problem is particularly acute in the area of cytology" said Nikos Pavlidis, acting president of Diagnostic Solutions at BD. "This solution helps solve for the dearth of expert cytologists by leveraging new AI-based digital technology to make the testing process efficient and bring the traditional Pap test into the 21st century."
The Techcyte platform is compatible with the most common liquid based cytology (LBC) preparations, including BD SurePath™ Liquid-based Pap Test vial and aims to be compatible with several of the most-used whole-slide imagers on the market.
"Eye strain, fatigue, distractions, and intense workloads can make manually reading Pap smears difficult," said Ben Cahoon, CEO of Techcyte. "Our digital workflow supported by an AI-based algorithm can assist lab professionals in delivering consistent results for their patients. Our system presents the most diagnostically relevant cell images to guide the cytotechnologists and pathologists for efficient review and better decision making."
Globally, cervical cancer kills more than 340,000 women annually. It is the fourth most frequently observed cancer in women, and its high mortality rate could be reduced through a comprehensive approach that includes effective screening. Although the guidance within health care is shifting to recommending HPV screening as the primary test for cervical cancer, Pap tests will continue to play an important diagnostic role, as programs are transitioning to the new standard of care and in looking for precancer and cancer when a high-risk HPV infection is detected. One in 10 HPV tests are positive and positive results are then referred to a Pap test for visual inspection of cells.
The Techcyte system is CE-marked per the IVD directive (98/79/EC) for clinical use in
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics, and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson.
BD Contacts: | |
Media: | Investors: |
Troy Kirkpatrick | Adam Reiffe |
VP, Public Relations | Sr. Director, Investor Relations |
858.617.2361 | 201.847.6927 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-techcyte-announce-strategic-collaboration-to-offer-ai-based-digital-cervical-cytology-system-for-pap-testing-302047491.html
SOURCE BD (Becton, Dickinson and Company)
FAQ
What is the strategic collaboration agreement announced by BD and Techcyte?
What is the aim of the AI-based algorithm offered by BD and Techcyte?
What is the availability of the Techcyte system in Europe?
What is the status of FDA approval for clinical use of the Techcyte system in the U.S.?
What is the aim of the AI-based algorithm in the digital cervical cytology system?
